Taiwan Liposome Company, Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Keelung Hong
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 3 Yuanqu Street Taipei Taiwan, Province of China 11503
- IPO Date
- Nov 21, 2018
- CIK
- 0001722890
- Website
- tlcbio.com
- Similar Companies
- Business
- Taiwan Liposome Company, Ltd. (TLC) develops and commercializes liposomal and nanoparticle-based therapeutics for cancer, infectious diseases, and other medical conditions. The company offers a pipeline of proprietary products including TLC ELL-88 (liposomal irinotecan) for pancreatic cancer and small cell lung cancer; TLC C, a nanoliposomal amphotericin B antifungal; and nanoliposomal formulations of antibiotics and anticancer agents such as mitomycin and topotecan. TLC provides research and development services in liposome and nanoparticle drug delivery technologies, including custom formulation development and clinical trial support; it also licenses intellectual property for liposomal delivery systems. Founded in 1997 and headquartered in Taipei, Taiwan, TLC operates primarily in Asia with clinical trials and partnerships extending to North America and Europe, targeting pharmaceutical companies, hospitals, and biotech firms in oncology and anti-infective markets. In late 2023, TLC announced positive topline results from its Phase 3 RESOLUTE trial of TLC ELL-88, demonstrating superior efficacy over standard irinotecan in first-line small cell lung cancer treatment, paving the way for regulatory submissions; the company also expanded manufacturing capacity through a strategic alliance with a U.S.-based CDMO in 2024 and secured a $50 million funding round led by existing investors to advance pipeline commercialization. Additionally, TLC rebranded its corporate identity to TLC Bio in early 2025 to reflect its evolution into a full-spectrum biopharma platform, while initiating a Phase 2 trial for TLC C in invasive fungal infections.
TLC International Equity Portfolio Q1 2026 Leaders And Laggards
Gen5 TLC, BiCS8 Pipeline Power Sandisk's Data Center Growth Ambitions
Pets at Home needs some TLC after tough year
Glad® and T-Boz Bring `90s Nostalgia to the Household Cleaning Experience
Life Science Equipment Market to be Worth $97.96 Billion by 2031 - Exclusive Report by Meticulous Research®
Samsung Electronics Begins Industry’s First Mass Production of 9th-Gen V-NAND
Samsung Electronics Begins Industry’s First Mass Production of 9th-Gen V-NAND
Highlights of Dr. David Hunter's Oral Presentation at ACR's Late Breaking Abstracts Session
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
Shining a light on School Nutrition and the Lunchtime Heroes that make it happen
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares
TLC Reports Second Quarter 2021 Financial Results and Provides Business Update
Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop
TLC Announces Details of Stock Swap Transactions
TLC Stock Price: 28.69% Increase Explanation
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?
TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment
TLC Stock Price: Over 6% Increase Pre-Market Explanation
TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India